OQROGet OQRO Pro
Politician trade (Senate)

Vertex Pharmaceuticals (VRTX)Sen. Alan Armstrong disclosed a purchase $1K–$15K

Sen. Alan Armstrong disclosed a purchase of Vertex Pharmaceuticals in the $1K–$15K range.

$1,001–$15,000
Reported range · official band, not an exact amount
116 days
Disclosure lag
Traded
Mar 27, 2026
Disclosed
Jul 21, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jan 29, 2026CongressDisclosed sale of VRTX — reported range $1,001 - $15,000
  2. Feb 11, 2026Insider · 5 peopleInsiders: 5 sales (~$3.5M)
  3. Feb 12, 2026Company filing · Form 8-K · ResultsReported its results
  4. Feb 12, 20265% stakeCapital Research Global Investors reported a passive stake (13G) of 6.8%
  5. Feb 13, 2026Insider · 3 peopleInsiders: 3 sales (~$1.4M)
  6. Feb 17, 2026Insider · 5 peopleInsiders: 5 sales (~$4.5M)
  7. Feb 18, 2026Insider · 5 peopleInsiders: 5 sales (~$2.0M)
  8. Feb 19, 2026Insider · 1 personInsiders: 8 sales (~$27.5M)
  9. Feb 25, 2026Insider · 7 peopleInsiders: 8 sales (~$4.6M)
  10. Feb 26, 2026InsiderOfficer sold ~$173K of VRTX shares in the open market
  11. Feb 27, 2026Insider · 2 peopleInsiders: 14 sales (~$20.9M)
  12. Mar 2, 2026InsiderOfficer sold ~$442K of VRTX shares in the open market
  13. Mar 4, 2026InsiderOfficer sold ~$1.16M of VRTX shares in the open market
  14. Mar 11, 2026InsiderOfficer sold ~$1.31M of VRTX shares in the open market
  15. Mar 13, 2026InsiderOfficer sold ~$1.12M of VRTX shares in the open market
  16. Mar 27, 2026 · this disclosureCongressDisclosed purchase of VRTX — reported range $1,001 - $15,000

What came next

  1. Mar 27, 2026FDAFDA drug approval: Alyftrek
  2. Mar 27, 2026FDAFDA drug approval: Trikafta (Copackaged)
  3. Mar 27, 2026FDAFDA drug approval: Trikafta (Copackaged)
  4. Mar 27, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  5. Mar 27, 2026InsiderOfficer sold ~$1.05M of VRTX shares in the open market
  6. Apr 1, 2026InsiderOfficer sold ~$439K of VRTX shares in the open market
  7. Apr 28, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On April 28, 2026, Suketu Upadhyay informed the board of directors (the “Board”) of Vertex Pharmaceuticals Incorporated (the “Company”) of his decision not to stand for re-election as a director of the Company at the Company’s 2026 annual meeting of shareholders (the “2026 Annual Meeting”).”
  8. Apr 30, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
  9. May 1, 2026InsiderOfficer sold ~$469K of VRTX shares in the open market
  10. May 4, 2026Company filing · Form 8-K · ResultsReported its results
  11. May 4, 2026InsiderDirector sold ~$135K of VRTX shares in the open market
  12. May 12, 2026Insider · Their largest sale since 2023Officer sold ~$3.14M of VRTX shares in the open market
  13. May 13, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On March 27, 2026, the Board of Directors (the "Board") of Vertex Pharmaceuticals Incorporated (the "Company") approved the Vertex Pharmaceuticals Incorporated 2026 Stock and Option Plan (the "2026 Plan"), which replaces the Vertex Pharmaceuticals Incorporated 2013 Stock and Option Plan, subject to shareholder approval.”
  14. May 14, 20265% stakeCapital Research Global Investors reported a passive stake (13G) of 8.3%
  15. May 14, 20265% stakeCapital World Investors reported a passive stake (13G) of 10.1%
  16. May 15, 2026Insider · 2 peopleInsiders: 2 sales (~$629K)
  17. May 29, 2026InsiderOfficer sold ~$888K of VRTX shares in the open market
  18. Jun 1, 2026InsiderOfficer sold ~$364K of VRTX shares in the open market
  19. Jun 5, 2026InsiderOfficer sold ~$785K of VRTX shares in the open market
  20. Jun 15, 2026InsiderOfficer sold ~$1.83M of VRTX shares in the open market
View the official recordSenate eFD periodic transaction report

How to read Senate eFD periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Vertex Pharmaceuticals

For Vertex Pharmaceuticals, OQRO holds 2 Congress trade reports and 42 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its VRTX page.

Other recent filings by Sen. Alan Armstrong

The full history of Sen. Alan Armstrong is on the profile page.

How this filing works

Other disclosures at Vertex Pharmaceuticals

Everything OQRO holds on this company is on its VRTX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data